This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp Limited. Active years: 2025-2026.
Company Filing History:
1 out of 10 
1 out of 31 
1 out of 29 Years Active: 2025-2026
Title: The Innovations of Inventor Zi Chen
Introduction
Zi Chen is a notable inventor based in Suzhou, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific cancer pathways. His work is characterized by a focus on innovative treatments for hematologic malignancies.
Latest Patents
Zi Chen holds a patent for N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors. This patent describes methods of treating hematologic malignancies in patients by administering a Bcl-2 inhibitor through a step-wise dosing regimen. His innovative approach aims to improve treatment outcomes for patients in need.
Career Highlights
Throughout his career, Zi Chen has worked with Ascentage Pharma (Suzhou) Co., Ltd. and Ascentage Pharma Group Corp Limited. His experience in these companies has allowed him to contribute to the advancement of cancer therapies and to collaborate with leading experts in the field.
Collaborations
Zi Chen has collaborated with notable colleagues such as Yifan Zhai and Dajun Yang. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in cancer treatment.
Conclusion
Zi Chen's contributions to the field of pharmaceuticals, particularly through his patent on Bcl-2 inhibitors, highlight his role as an influential inventor. His work continues to pave the way for advancements in cancer treatment, showcasing the importance of innovation in healthcare.